DLBCL Clinical Trial Tracker — Monitor Diffuse Large B-Cell Lymphoma Research

DLBCL clinical trial activity in 2026

Diffuse large B-cell lymphoma remains the most common aggressive lymphoma and one of the most active areas of hematologic oncology clinical development. Multiple approved therapies — including axicabtagene ciloleucel, lisocabtagene maraleucel, tisagenlecleucel, and bispecific antibodies epcoritamab and glofitamab — have transformed the treatment landscape. With 40 active trials on ClinicalTrials.gov and 17 currently recruiting, the field continues to advance at pace.

Key signals to monitor:

• Next-generation CAR-T products with improved persistence, allogeneic platforms, and combination regimens
• CD20×CD3 and CD79b×CD3 bispecific antibody programs in first- and later-line settings
• R-CHOP modifications — novel induction regimens attempting to improve the ~40% relapse rate
• Polatuzumab vedotin follow-on ADC combinations and new ADC targets (CD22, CD79b)
• Lenalidomide and novel IMiD combinations in non-GCB/ABC DLBCL
• High-grade B-cell lymphoma with MYC/BCL2/BCL6 rearrangements — "double/triple-hit" subtypes

What we monitor for DLBCL

Configure your DLBCL profile with the following options:

• Condition keywords: "diffuse large B-cell lymphoma", "DLBCL", "large B-cell lymphoma", "high-grade B-cell lymphoma", "primary CNS lymphoma"
• Phase filter: Phase 1 for early pipeline, Phase 2/3 for registration-enabling studies
• Sponsor filter: Industry-sponsored for competitive intelligence, or all sponsors
• Status filter: Recruiting only, or all active studies including not yet recruiting

The DLBCL treatment landscape in 2026

Bispecific antibodies in earlier lines

Epcoritamab (Epkinly) and glofitamab (Columvi) approvals in relapsed/refractory disease have generated extensive Phase 2/3 trial activity moving bispecifics into earlier treatment lines — including as part of first-line combinations. Multiple trials are registering enrolling both transplant-eligible and -ineligible patients. Tracking which combinations are being registered by which companies reveals which bispecific platforms are gaining first-mover advantage in the front-line space.

CAR-T evolution: persistence, manufacturing, and allogenic

While axicabtagene, lisocabtagene, and tisagenlecleucel are approved in DLBCL, next-generation programs are addressing key limitations: manufacturing time, T cell exhaustion, and access barriers of autologous production. Allogeneic CAR-T programs, "armored" CAR-T with cytokine payloads, and in-vivo CAR-T generation platforms are all in early clinical development for large B-cell lymphoma.

First-line innovations beyond R-CHOP

Despite decades of R-CHOP as the first-line standard, approximately 40% of patients relapse or are refractory. The POLARIX trial established pola-R-CHP as a new option for high-risk patients. Now, trials are testing bispecific + chemo combinations, CAR-T as consolidation, and molecular subtype-directed first-line approaches for MYC-high and ABC-subtype DLBCL.

High-grade lymphoma subtypes

"Double-hit" and "triple-hit" B-cell lymphoma with concurrent MYC, BCL2, and/or BCL6 rearrangements carry a poor prognosis despite intensive induction chemotherapy. Multiple trials are examining novel first-line regimens for these high-risk patients, including venetoclax-based combinations, CAR-T consolidation, and dose-adjusted EPOCH variants.

Who uses DLBCL trial monitoring

Hematology-oncology pharma BD and CI teams

Companies with DLBCL programs track competitor trial registrations as the earliest public signal of clinical strategy. A new Phase 2 bispecific combination trial is a months-early indicator of competitive positioning in first-line or relapsed/refractory settings.

Hematologists at academic medical centers

DLBCL physicians monitor trial registrations to identify cooperative group studies open at their institutions and to understand emerging treatment paradigms before they reach clinical guidelines.

Oncology biotech investors

DLBCL is a high-value indication with established commercial precedents for CAR-T and bispecifics. Investors tracking Phase 1 trial registrations gain earlier visibility into program value than those relying on conference announcements.

Frequently asked questions

Can I track other aggressive lymphoma subtypes together with DLBCL?

Yes. Add keywords like "follicular lymphoma", "mantle cell lymphoma", or "primary mediastinal B-cell lymphoma" to a single profile, or create separate profiles for each subtype on the Starter plan ($49/month).

How current is the DLBCL trial data?

Our pipeline fetches from ClinicalTrials.gov every morning. Studies posted or updated in the preceding 24 hours appear in that day's digest.

How is this different from ClinicalTrials.gov alerts?

ClinicalTrials.gov email alerts lack phase filtering, sponsor type filtering, and clean digest formatting. DataLookout provides filtered, labeled alerts — the intelligence layer on top of the raw registry data — making it easy to spot new DLBCL trial registrations in the flood of daily ClinicalTrials.gov updates.